Fåhraeus Startup & Growth AB

Overview

Fåhraeus Startup & Growth AB is a venture capital firm specializing in early-stage investments within the life science and technology sectors. The firm focuses on high-growth startups, providing capital and strategic support to help companies scale. Their investment approach is hands-on, leveraging sector expertise and a broad network of operators, founders, and strategic partners to support portfolio companies. The firm's investment strategy targets commercial-stage companies where life science intersects with technology, including healthtech, medtech, and digital diagnostics. They partner with companies demonstrating strong product-market fit, scalable business models, and the potential to become category leaders. Fåhraeus Startup & Growth AB is highly selective in therapeutics, typically investing only in clinically de-risked phases. Since its inception in 2021, Fåhraeus Startup & Growth AB has been actively investing in the Nordic region and across Europe. Their portfolio includes companies such as Saga Dx, Promimic, OssDsign, Din Psykolog, BrightBid, and Aplagon. The firm closed its second fund, FSG Fund II, at €75 million in February 2025, with the European Investment Fund (EIF) joining as a key investor. This fund aims to expand their portfolio and support early-stage companies in scaling their operations. Fåhraeus Startup & Growth AB is led by an experienced team, including Christer Fåhraeus, Linus Wiebe, Johanna Asklin, Emanuel Stihl, and Alexander Jöndell. The firm is headquartered in Lund, Skåne County, Sweden, and operates with a team of 2-10 employees. Their investment philosophy emphasizes a hands-on approach, providing not only capital but also strategic guidance to foster growth and innovation within their portfolio companies.

Investment Focus

• Strong product-market fit
• Scalable business model
• Potential to become category leader
• Clinically de-risked phase for therapeutics

Portfolio Companies